Methadone associated long term hearing loss and nephrotoxicity; a case report and literature review.


Journal

Substance abuse treatment, prevention, and policy
ISSN: 1747-597X
Titre abrégé: Subst Abuse Treat Prev Policy
Pays: England
ID NLM: 101258060

Informations de publication

Date de publication:
06 11 2019
Historique:
received: 04 04 2019
accepted: 22 10 2019
entrez: 8 11 2019
pubmed: 7 11 2019
medline: 6 5 2020
Statut: epublish

Résumé

Methadone is a long-acting opioid receptor agonist. Reported adverse effects of methadone include constipation, respiratory depression, dizziness, nausea, vomiting, itching, sweating, rhabdomyolysis, QT prolongation, and orthostatic hypotension. Hearing loss has been rarely reported following methadone use, and when reported, long term follow-up is rare. Herein we report a case of methadone poisoning with rhabdomyolysis, acute kidney injury, and persistent hearing loss documented by a 2 year follow up. The patient was a 34 years old male who presented with a reduced level of consciousness and acute hearing loss after suicidal ingestion of 40 mg of methadone while experiencing family-related stresses. He had no prior history of methadone use, abuse, or addiction. Initial laboratory testing was significant for a serum creatinine concentration of 4.1 mg/dl, a mixed metabolic and respiratory acidosis, thrombocytopenia, abnormal hepatic transaminases, and coagulation tests. The patient then developed severe rhabdomyolysis. Also, audiometry showed a bilateral sensorineural hearing loss. The patient required hemodialysis for 11 days while his metabolic abnormalities gradually resolved. However, his hearing loss was persistent, as demonstrated by 2 years of follow up. Our patient simultaneously had kidney failure, rhabdomyolysis, and permanent hearing loss following methadone poisoning. Although rare, ototoxicity and permanent hearing loss may happen in cases of methadone poisoning. While opioid-induced hearing loss is uncommon, methadone toxicity should be taken into account for any previously healthy patient presenting with acute hearing loss with or without rhabdomyolysis.

Sections du résumé

BACKGROUND
Methadone is a long-acting opioid receptor agonist. Reported adverse effects of methadone include constipation, respiratory depression, dizziness, nausea, vomiting, itching, sweating, rhabdomyolysis, QT prolongation, and orthostatic hypotension. Hearing loss has been rarely reported following methadone use, and when reported, long term follow-up is rare. Herein we report a case of methadone poisoning with rhabdomyolysis, acute kidney injury, and persistent hearing loss documented by a 2 year follow up.
CASE PRESENTATION
The patient was a 34 years old male who presented with a reduced level of consciousness and acute hearing loss after suicidal ingestion of 40 mg of methadone while experiencing family-related stresses. He had no prior history of methadone use, abuse, or addiction. Initial laboratory testing was significant for a serum creatinine concentration of 4.1 mg/dl, a mixed metabolic and respiratory acidosis, thrombocytopenia, abnormal hepatic transaminases, and coagulation tests. The patient then developed severe rhabdomyolysis. Also, audiometry showed a bilateral sensorineural hearing loss. The patient required hemodialysis for 11 days while his metabolic abnormalities gradually resolved. However, his hearing loss was persistent, as demonstrated by 2 years of follow up.
CONCLUSION
Our patient simultaneously had kidney failure, rhabdomyolysis, and permanent hearing loss following methadone poisoning. Although rare, ototoxicity and permanent hearing loss may happen in cases of methadone poisoning. While opioid-induced hearing loss is uncommon, methadone toxicity should be taken into account for any previously healthy patient presenting with acute hearing loss with or without rhabdomyolysis.

Identifiants

pubmed: 31694678
doi: 10.1186/s13011-019-0236-z
pii: 10.1186/s13011-019-0236-z
pmc: PMC6836333
doi:

Substances chimiques

Analgesics, Opioid 0
Methadone UC6VBE7V1Z

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

48

Références

Pharmacotherapy. 2015 Jul;35(7):e118-21
pubmed: 26112082
Eur Arch Otorhinolaryngol. 2009 May;266(5):773-4
pubmed: 19263068
Addiction. 2001 Sep;96(9):1363-4
pubmed: 11683145
Laryngoscope. 1978 Sep;88(9 Pt 1):1518-21
pubmed: 682808
Am J Forensic Med Pathol. 2013 Mar;34(1):1-4
pubmed: 23361067
Springerplus. 2016 Dec 9;5(1):2087
pubmed: 28018795
Case Rep Med. 2013;2013:242730
pubmed: 23983704
Clin Toxicol (Phila). 2018 Jan;56(1):74-76
pubmed: 28650702
Can Med Assoc J. 1976 Apr 3;114(7):596
pubmed: 944084
Am J Audiol. 2010 Dec;19(2):86-90
pubmed: 20966353
Eur Arch Otorhinolaryngol. 2008 May;265(5):603-6
pubmed: 17968577
Am J Otol. 2000 Mar;21(2):188-91
pubmed: 10733182
J Emerg Med. 2011 Dec;41(6):635-9
pubmed: 21145191
Pain Physician. 2008 Mar;11(2 Suppl):S105-20
pubmed: 18443635
Laryngoscope. 2010 May;120(5):1011-21
pubmed: 20422698
Eur J Neurosci. 2006 May;23(10):2701-11
pubmed: 16817873
Hear Res. 2003 Jul;181(1-2):85-93
pubmed: 12855366
J Toxicol Clin Toxicol. 1983 Jun;20(4):353-60
pubmed: 6655775
Neurology. 2000 Jun 27;54(12):2345
pubmed: 10881270
Ann Pharmacother. 2010 Jan;44(1):207-10
pubmed: 20028962
Pain Physician. 2007 May;10(3):467-72
pubmed: 17525781
Trends Amplif. 2011 Sep;15(3):91-105
pubmed: 21606048
Int J Clin Pract Suppl. 2005 Apr;(147):128-9
pubmed: 15875650
Laryngol Rhinol Otol (Stuttg). 1979 May;58(5):435-7
pubmed: 449504
EXCLI J. 2015 May 05;14:577-600
pubmed: 26869865
Nephron. 1992;62(3):362
pubmed: 1436354
Acta Psychiatr Scand. 2009 Jul;120(1):76-9
pubmed: 19392810
Case Rep Otolaryngol. 2014;2014:962759
pubmed: 24516766
Pain Med. 2011 May;12(5):747-54
pubmed: 21332934
Am J Otolaryngol. 2013 Nov-Dec;34(6):735-8
pubmed: 24051235
Iran J Med Sci. 2017 Jul;42(4):327-346
pubmed: 28761199

Auteurs

Saeedeh Ghasemi (S)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences, Ghaffari Avenue, Vali-Asr hospital, Birjand, Iran.

Shadi Izadpanahi (S)

Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran.

Mohammad Ali Yaghoubi (MA)

Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Jeffrey Brent (J)

Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.

Omid Mehrpour (O)

Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences, Ghaffari Avenue, Vali-Asr hospital, Birjand, Iran. omid.mehrpour@yahoo.com.au.
Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, 1391 Speer Blvd, Denver, CO, 80204, USA. omid.mehrpour@yahoo.com.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH